Day 3 Program

Poster Spotlight 6: Are We Listening to Every Patient? Digital Tools, Patient-Reported Outcomes and Dispartities in Breast Cancer

Day 3: December 10, 2026

7:00 AM–8:30 AM CST

301 ABC

Session Details

Moderator

Melissa L Bondy

PS6-1

Behavioral profiles associated with adherence to adjuvant endocrine therapy: a retrospective population-based cohort study

Aaron Dibner-Dunlap, Surgo Health, Washington, DC

PS6-2

Symptom Episodes in CDK4/6 Inhibitor Therapy: Real-World Evidence from Electronic Patient-Reported Outcomes on a Therapy Intelligence Platform

Paul Buzinec, Dosentrx, Plymouth, MN

PS6-3

Online mindfulness intervention for patients receiving chemotherapy for breast cancer: A randomized controlled trial

Fernanda Mesa-Chavez, School of Medicine and Health Sciences, Monterrey, Mexico

PS6-4

An Intervention to Promote Job Retention during (Neo)Adjuvant Chemotherapy: Talking to Employers and Medical Staff about Work (TEAMWork)

Victoria Blinder, Memorial Sloan Kettering Cancer Center, New York, NY

PS6-5

What are Breast Cancer patients Really Talking About? A Natural Language Analysis of Patient Messages Across Clinical and Peer Channels

Neil Margolis, Outcomes4Me, Inc., Boston, MA

PS6-6

Topic 1: There's an App for That: Digital and Mindfulness-Based Support Through Breast Cancer Treatment

Abirami Sivapiragasam, Medical University of South Carolina, Charleston, SC

PS6-7

Balancing prolonged progression and quality of life: palbociclib combination therapy for HR+/HER2-positive advanced breast cancer

Justin Yu, Pfizer Inc, New York, NY

PS6-8

Inhibition of mTOR and disparity in breast cancer survival: secondary analysis of SWOG S1207, a randomized phase 3 clinical trial of adjuvant everolimus in high-risk, hormone receptor-positive, early-stage breast cancer

Kent F. Hoskins, University of Illinois Chicago and University of Illinois Cancer Center, Chicago, IL

PS6-9

Impact of environmental hazard burden, somatic genomic profiles, and race on outcomes in metastatic breast cancer

Emily L Podany, Washington University in St. Louis, St. Louis, MO

PS6-10

Health-related quality of life after 5- versus 15-fraction breast irradiation with simultaneously integrated boost: 2-year results from the randomized phase III YO-HAI5 trial

Renée De Noyette, Ghent University, Ghent, Belgium

PS6-11

Total symptom burden is strongly associated with tolerance of neoadjuvant breast cancer therapy as captured by FACT-GP5

Amrita Basu, University of California San Francisco, San Francisco, CA

PS6-12

Topic 2: Measuring What Matters: Patient-Reported Outcomes and Disparities in Breast Cancer Clinical Trials

Katie E Reeder-Hayes, University of North Carolina at Chapel Hill, Chapel Hill, NC